Kymera Therapeutics Celebrates 10-Year Anniversary

Biotech company highlights disciplined approach to targeting unmet needs

Mar. 12, 2026 at 5:12pm

Got story updates? Submit your updates here. ›

Kymera Therapeutics, a biotech company focused on targeted protein degradation, is celebrating its 10-year anniversary next month. The company was founded with a strategic approach to target selection, focusing on biological pathways that had not been addressed by conventional small molecule technologies but had large markets of unmet need. This disciplined approach was aimed at de-risking the development of new therapeutics.

Why it matters

Kymera's milestone highlights the company's success in pioneering a novel therapeutic modality over the past decade. Targeted protein degradation represents an exciting new approach in drug development that could unlock treatments for diseases with high unmet need. Kymera's ability to sustain its operations and advance its pipeline through this innovative science demonstrates the potential of the company's strategy.

The details

Kymera Therapeutics was founded 10 years ago to capitalize on the emerging field of targeted protein degradation. The company took a disciplined approach, focusing on biological pathways that had not been addressed by conventional small molecule drugs but represented large market opportunities. This strategy was intended to de-risk Kymera's drug development efforts by targeting validated pathways while exploring novel therapeutic modalities.

  • Kymera Therapeutics was founded 10 years ago.
  • The company will celebrate its 10-year anniversary next month.

The players

Kymera Therapeutics

A biotech company focused on developing novel therapeutics using targeted protein degradation.

Bruce Jacobs

The Chief Financial Officer of Kymera Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Kymera is actually coming up next month on our 10-year anniversary of the company's founding.”

— Bruce Jacobs, Chief Financial Officer (Seeking Alpha)

“From the beginning, the company was founded to really capitalize on this exciting new modality, targeted protein degradation. And we approached it in a, I would say, a little bit of a unique way with a very disciplined, and I would argue, strategic approach to target selection, where we went into this company formation, this endeavor with a focus on targets that had not been addressed with conventional technologies, conventional small molecule technologies, where there were large markets of unmet need, but where there were proven and known biological pathways.”

— Bruce Jacobs, Chief Financial Officer (Seeking Alpha)

What’s next

Kymera Therapeutics is expected to provide updates on its pipeline and business progress as it celebrates its 10-year anniversary next month.

The takeaway

Kymera Therapeutics' 10-year milestone demonstrates the company's successful execution of a disciplined strategy to develop innovative therapies targeting unmet medical needs through the novel approach of targeted protein degradation.